| Literature DB >> 33402303 |
Tatsuya Kodama1, Hirofumi Obinata2, Hitoshi Mori3, Wakana Murakami4, Yohsuke Suyama5, Hisashi Sasaki6, Yuji Kouzaki7, Shuichi Kawano6, Akihiko Kawana7, Satoshi Mimura6.
Abstract
INTRODUCTION: In patients with severe coronavirus disease 2019 (COVID-19), respiratory failure is a major complication and its symptoms occur around one week after onset. The CURB-65, A-DROP and expanded CURB-65 tools are known to predict the risk of mortality in patients with community-acquired pneumonia. In this retrospective single-center retrospective study, we aimed to assess the correlations of the A-DROP, CURB-65, and expanded CURB-65 scores on admission with an increase in oxygen requirement in patients with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pneumonia.Entities:
Keywords: A-DROP; COVID-19; CURB-65; Expanded CURB-65; SARS-CoV-2 pneumonia
Mesh:
Substances:
Year: 2020 PMID: 33402303 PMCID: PMC7833485 DOI: 10.1016/j.jiac.2020.12.009
Source DB: PubMed Journal: J Infect Chemother ISSN: 1341-321X Impact factor: 2.211
Characteristics of the patients.
| All patients (N = 207) | |
|---|---|
| Basic information | |
| Age, years [median (25%, 75%)] | 50 (40, 71) |
| Male gender, n (%) | 121 (59) |
| Nationality | |
| Asia including Japan, n (%) | 185 (89) |
| Japan, n (%) | 158 (76) |
| Europe, n (%) | 5 (2) |
| North or South America | 12 (6) |
| Oceania, n (%) | 5 (2) |
| Smoking status | |
| Current or ex-smoker, n (%) | 66 (32) |
| Never smoker, n (%) | 141 (68) |
| Comorbidities | |
| Any, n (%) | 101 (49) |
| Cardiovascular disease, n (%) | 12 (6) |
| Diabetes, n (%) | 12 (6) |
| Chronic respiratory disorder, n (%) | 20 (10) |
| Malignancy, n (%) | 6 (3) |
| Asymptomatic cases, n (%) | 40 (19) |
| Symptomatic cases, n (%) | 167 (81) |
| Patients with respiratory failureexcept for those who required HOT, n (%) | 8 (4) |
| Nasal canula | 5 (2) |
| Oxygen mask | 3 (1) |
| Time from symptom onset to presentation, days median[median (25%, 75%)] | 5 (4, 8) |
| Fever, n (%) | 63 (30) |
| Cough, n (%) | 79 (38) |
| Headache, n (%) | 26 (13) |
| Fatigue, n (%) | 44 (21 |
| Sore throat, n (%) | 21 (10) |
| Diarrhea, n (%) | 17 (8) |
| Nasal discharge, n (%) | 26 (13) |
| Dyspnea, n (%) | 24 (12) |
| White blood cell, 104/μL | 5290 (4060, 6530) |
| Lymphocyte count, 104/μL | 1252 (860, 1694) |
| Platelet, 104/μL[median (25%,75%)] | 21.2 (17.5, 26.6) |
| Albumin, g/dL | 4.1 (3.8, 4.3) |
| CRP, mg/dL[median (25%,75%)] | 0.73 (0.13, 2.79) |
| BUN, mg/dL[median (25%,75%)] | 13 (11, 17) |
| LDH (mg/L), IU/L | 211 (177, 266) |
| AST, IU/L[median (25%,75%)] | 27 (21, 37) |
| ALT, IU/L[median (25%,75%)] | 27 (17, 42) |
| Severe patients, n (%) | 40 (19) |
| Nasal canula or oxygen mask, n (%) | 23 (11) |
| Non-invasive positive pressure ventilationor high flow nasal, n (%) | 11 (5) |
| Intubation, n (%) | 6 (3) |
| Death, n (%) | 3 (1) |
HOT = home oxygen therapy; CRP= C-reactive protein; BUN = blood urea nitrogen; LDH = lactate dehydrogenase; AST = aspartate aminotransferase; ALT = alanine aminotransferase.
Fig. 1The proportions of SARS-CoV-2 pneumonia patients with an increase in severity for each subgroup of A-DROP, Curb-65 and expanded Curb-65 and the correlation between each of the three scoring systems and the increase in severity.
Fig. 2ROC curves for three scoring systems of SARS-CoV-2 pneumonia patients.
Statistical significance of clinical findings for severe patients who increased in oxygen requirement, and non-severe patients.
| severe | non-severe | P-value | |
|---|---|---|---|
| 0.53 | |||
| Asia | 35 (88) | 151 (90) | |
| Europe | 0 (0) | 4 (2) | |
| North or South America | 3 (8) | 9 (5) | |
| Oceania | 2 (5) | 3 (2) | |
| 14 (35) | 52 (31) | 0.11 | |
| Cardiovascular disease | 5 (13) | 7 (4) | 0.04 |
| Diabetes | 3 (8) | 9 (5) | 0.61 |
| Hypertension | 9 (23) | 24 (14) | 0.88 |
| Chronic respiratory disorder | 5 (13) | 15 (9) | 0.5 |
| Malignancy | 1 (3) | 5 (3) | 0.87 |
| 10 (25) | 70 (42) | <0.05 | |
| Blood pressure (sBP< 90 mmHg or dBP< 60 mmHg) | 2 (5) | 7 (4) | 0.82 |
| Respiratory rate (≧30/min) | 4 (10) | 2 (1) | <0.01 |
| BUN (>19 mg/dL) | 8 (20) | 21 (13) | 0.22 |
| Albumin (<3.5 g/dL) | 9 (23) | 12 (7) | <0.01 |
| LDH (>230 u/L) | 27 (68) | 52 (31) | <0.001 |
| Lymphopenia (<800/μL) | 14 (35) | 33 (19.7) | 0.04 |
| elevation of CRP (≧10 mg/dL) | 11 (28) | 5 (3) | <0.001 |
| elevation of liver enzyme (AST> 40 IU/L and/or ALT> 40 IU/L) | 19 (48) | 43 (26) | 0.001 |
| elevation of D-dimer (>1 mg/dL) (N = 92) | N = 39 | N = 53 | <0.001 |
| 9 (4.5, 13) | 3 (2, 7) | <0.001 | |
sBP = systolic blood pressure; dBP = diastolic blood pressure; BUN = blood urea nitrogen; LDH = lactate dehydrogenase; CRP= C-reactive protein; AST = aspartate aminotransferase; ALT = alanine aminotransferase.